Effect of Catheter Ablation and Antiarrhythmic Drugs on Cognitive Function in Patients Aged 60-80 with Mild Cognitive Impairment and Persistent Atrial Fibrillation

What this Trial Is About

Researchers are evaluating how catheter ablation for persistent atrial fibrillation affects cognitive function in patients who have mild cognitive impairment. This trial compares two groups one receiving antiarrhythmic drugs alone and the other receiving both atrial fibrillation ablation and antiarrhythmic drugs. The study aims to understand the impact of these treatments on cognitive abilities. Participants in the ablation group will undergo catheter ablation using energy sources like radiofrequency, cryoballoon, or pulsed field ablation, with pulmonary vein isolation as a mandatory part of the procedure. Those in the drug-only group will start antiarrhythmic medications such as amiodarone, flecainide, propafenone, or sotalol within one week of randomization if not already on them. Drug management may be adjusted by the treating physician. During the study, participants will have cognitive function assessed using the Montreal Cognitive Assessment questionnaire at the start and at 6 and 12 months after randomization. Other measures include changes in different cognitive functions, atrial fibrillation burden, and quality of life surveys. The study will monitor these outcomes to evaluate the effects of the treatments over time.

EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment